SCHEMBL2815840

SCHEMBL2815840

CNc1nc2ccccc2n2cc(-c3ccc(Br)cc3)nc12

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.63
KDM4E B2RXH2 2/20 0.51
TOP2A P11388 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ADORA1 P30542 2/20 0.50
HTR2C P28335 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
BRD4 O60885 1/20 0.41
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2816349 0.89 KDM4E (0.63) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2817799 0.87 ADORA2A (0.63) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2816214 0.87 ADORA2A (0.63) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2820944 0.87 KDM4E (0.51) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2818166 0.86 ADORA2A (0.65) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2820462 0.85 ADORA2A (0.67) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2816975 0.84 ADORA2A (0.65) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2818596 0.83 ADORA2A (0.50) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2816603 0.82 KDM4E (0.53) ADORA2AKDM4ETOP2AALDH1A1LMNA
SCHEMBL2820489 0.82 ADORA2A (0.60) ADORA2AKDM4ETOP2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS ADORA2A 1818/4885KDM4E 2878/4885TOP2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.